A safety look at currently available statins

Expert Opinion on Drug Safety

Volumn 1, Issue 3, 2002, Pages 269-274

  Moghadasian, Mohammed H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

aminotransferase; cholesterol; creatine kinase; myopathy; rhabdomyolysis; safety; statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ADOLESCENT; CHILD; CLINICAL TRIAL; DRUG INTERACTION; EXPERT WITNESS; HUMAN; REVIEW; SAFETY;

ADOLESCENT; ANTICHOLESTEREMIC AGENTS; CHILD; CLINICAL TRIALS; DRUG INTERACTIONS; EXPERT TESTIMONY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; SAFETY;

EID: 0041735202     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.1.3.269     Document Type: Review

References (33)

1. ENDO A, KURODA M: Citrinin, an inhibitor of cholesterol synthesis. J. Antibiot. (1976) 29:841-843.
2. FROHLICH J, FODOR G, MCPHERSON R, GENEST J, LANGNER N: Rationale for and outline of the recommendations of the working group on hypercholesterolemia and other dyslipidemias: interim report. Dyslipidemia Working Group of Health Canada. Can. J. Cardiol. (1998) 14(Suppl. A):17A-21A. (Pubitemid 28221280)
3. NO AUTHORS LISTED: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA (2001) 285:2486-2491.
4. SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383-1389.
5. MAAS INVESTIGATORS: Effect of simvastatin on coronary atheroma: The Multicenter Anti-Atheroma Study (MAAS). Lancet (1994) 344:633-638.
6. LIPID STUDY GROUP: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N. Engl. J. Med. (1998) 339:1349-1357.
7. SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol And Recurrent Events Trial investigators. N. Engl. J. Med. (1996) 335:1001-1009. (Pubitemid 26338729)
8. PITT B, MANCINI GB, ELLIS SG, ROSMAN HS, PARK JS, MCGOVERN ME: Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J. Am. Coll. Cardiol. (1995) 26:1133-11399.
9. SHEPHERD J, COBBE SM, FORD I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl. J. Med. (1995) 333:1301-1307.
10. BLANKENHORN DH, AZEN SP, KRAMSCH DM et al.: Coronary angiographic changes with lovastatin therapy: The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann. Intern. Med. (1993) 119:968-976.
11. DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air force/Texas Coronary Atherosclerosis Prevention Study. JAMA (1998) 279:1615-1622. (Pubitemid 28248586)
12. HERD JA, BALLANTYNE CM, FARMER JA et al.: Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am. J. Cardiol. (1997) 80:278-286. (Pubitemid 27330142)
13. MARAIS GE, LARSON KK: Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. Ann. Intern. Med. (1990) 112:228-230. (Pubitemid 20045213)
14. PIERCE LR, WYSOWSKI DK, GROSS TP: Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA (1990) 264:71-75. (Pubitemid 20209174)
15. GARNETT WR: Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am. J. Health. Syst. Pharm. (1995) 52:1639-1645.
16. DUELL PB, CONNOR WE, ILLINGWORTH DR: Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am. J. Cardiol. (1998) 81:368-369. (Pubitemid 28099321)
17. REAVEN P, WITZTUM JL: Lovastatin, nicotinic acid, and rhabdomyolysis. Ann. Intern. Med. (1988) 109:597-598.
18. BRISTOL-MYERS SQUIBB: Pravachol package insert. Princeton, NJ, USA (1993).
19. AHMAD S: Lovastatin, warfarin interaction. Arch. Intern. Med. (1990) 150:2404.
20. STERN R, ABEL R, GIBSON GL, BESSERER J: Atorvastatin does not alter the anticoagulant activity of warfarin. J. Clin. Pharmacol. (1997) 37:1062-1064. (Pubitemid 27524567)
21. PAN HY, TRISCARI J, DEVAULT AR et al.: Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin. Br. J. Clin. Pharmacol. (1991) 31:665-670.
22. NO AUTHORS LISTED: Compendium of Pharmaceuticals and Specialties (30th edn), Canadian Pharmacists Association, Ontario (1995):2483-2487.
23. ALEJANDRO DS, PETERSEN J: Myoglobinuric acute renal failure in a cardiac transplant patient taking lovastatin and cyclosporine. J. Am. Soc. Nephrol. (1994) 5:153-160. (Pubitemid 24977070)
24. LEES RS, LEES AM: Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N. Engl. J. Med. (1995) 333:664-665.
25. BRADFORD RH, DOWNTON M, CHREMOS AN et al.: Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia. Ann. Intern. Med. (1993) 118:850-855. (Pubitemid 23145408)
26. LECHLEITNER M, HOPPICHLER F, KONWALINKA G, PATSCH JR, BRAUNSTEINER H: Depressive symptoms in hypercholesterolemic patients treated with pravastatin. Lancet (1992) 340:910.
27. JEPPESEN U, GAIST D, SMITH T, SINDRUP SH: Statins and peripheral neuropathy. Eur. J. Clin. Pharmacol. (1999) 54:835-838. (Pubitemid 29051327)
28. JICK H, ZORNBERG GL, JICK SS, SESHADRI S, DRACHMAN DA: Statins and the risk of dementia. Lancet (2000) 356:1627-1631.
29. STEIN EA, ILLINGWORTH DR, KWITEROVICH PO JR et al.: Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA (1999) 281:137-144. (Pubitemid 29045345)
30. DUPLAGA BA: Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors. Ann. Pharmacother. (1999) 33:1224-1227.
31. SORELLE R: Baycol withdrawn from market. Circulation (2001) 104:E9015-E9016.
32. STAFFA JD, CHANG J, GREEN L: Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med. (2002) 346:539-540.
33. HEESCHEN C, HAMM CW, LAUFS U et al.: Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation (2002) 105:1446-1452. (Pubitemid 34263276)